MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

@inproceedings{Fan2016MiR125aPP,
  title={MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering
STAT3 expression},
  author={Zusen Fan and Hairong Cui and H Yu and Qing-Hai Ji and Liang Kang and Baohui Han and Jinxia Wang and Qiong Dong and Y Li and Zhifeng Yan and Xiaomei Yan and Xi-ping Zhang and Zhenxing Lin and Yaqi Hu and Shun Chang Jiao},
  booktitle={Oncogenesis},
  year={2016}
}
Cervical cancer (CC) is one of the most common malignancies in women. Paclitaxel is the front-line chemotherapeutic agent for treating CC. However, its therapeutic efficacy is limited because of chemoresistance, the mechanism of which remains poorly understood. Here, we used microRNA (miRNA) arrays to compare miRNA expression levels in the CC cell lines, HeLa and CaSki, with their paclitaxel resistance counterparts, HeLa/PR and CaSki/PR. We demonstrate that miR-125a was one of most… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
14 Citations
98 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 98 references

A phase 1 b dose - escalation study of TRC 105 ( anti - Endoglin antibody ) in combination with pazopanib in patients with advanced soft tissue sarcoma ( STS )

  • S Attia, R Riedel, S Robinson, R Conry, K Sankhala, B Seon
  • J Clin Oncol
  • 2015

Similar Papers

Loading similar papers…